169 related articles for article (PubMed ID: 32286506)
1. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation.
Costa LJ; Iacobelli S; Pasquini MC; Modi R; Giaccone L; Blade J; Schonland S; Evangelista A; Perez-Simon JA; Hari P; Brown EE; Giralt SA; Patriarca F; Stadtmauer EA; Rosinol L; Krishnan AY; Gahrton G; Bruno B
Bone Marrow Transplant; 2020 Sep; 55(9):1810-1816. PubMed ID: 32286506
[TBL] [Abstract][Full Text] [Related]
2. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
[TBL] [Abstract][Full Text] [Related]
3. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
4. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
Giralt S; Costa LJ; Maloney D; Krishnan A; Fei M; Antin JH; Brunstein C; Geller N; Goodman S; Hari P; Logan B; Lowsky R; Qazilbash MH; Sahebi F; Somlo G; Rowley S; Vogl DT; Vesole DH; Pasquini M; Stadtmauer E
Biol Blood Marrow Transplant; 2020 Apr; 26(4):798-804. PubMed ID: 31756536
[TBL] [Abstract][Full Text] [Related]
5. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Wei M; Xie C; Huang J; Liu Q; Lai Y
Hematology; 2023 Dec; 28(1):2269509. PubMed ID: 37850613
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
7. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
8. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only.
LeBlanc R; Claveau JS; Ahmad I; Delisle JS; Bambace N; Bernard L; Cohen S; Kiss T; Lachance S; Landais S; Roy DC; Sauvageau G; Roy J
Clin Transplant; 2020 Dec; 34(12):e14099. PubMed ID: 32981146
[TBL] [Abstract][Full Text] [Related]
9. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B
Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930
[TBL] [Abstract][Full Text] [Related]
10. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
Htut M; D'Souza A; Krishnan A; Bruno B; Zhang MJ; Fei M; Diaz MA; Copelan E; Ganguly S; Hamadani M; Kharfan-Dabaja M; Lazarus H; Lee C; Meehan K; Nishihori T; Saad A; Seo S; Ramanathan M; Usmani SZ; Gasparetto C; Mark TM; Nieto Y; Hari P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):478-485. PubMed ID: 29079457
[TBL] [Abstract][Full Text] [Related]
11. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
Gahrton G; Iacobelli S; Björkstrand B; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Carella AM; Beksac M; Bosi A; Milone G; Corradini P; Schönland S; Friberg K; van Biezen A; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Garderet L; Kröger N;
Blood; 2013 Jun; 121(25):5055-63. PubMed ID: 23482933
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after allogeneic stem cell transplantation in multiple myeloma.
Luoma S; Silvennoinen R; Rauhala A; Niittyvuopio R; Martelin E; Lindström V; Heiskanen J; Volin L; Ruutu T; Nihtinen A
Ann Hematol; 2021 Jun; 100(6):1553-1567. PubMed ID: 33866396
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Kharfan-Dabaja MA; Hamadani M; Reljic T; Nishihori T; Bensinger W; Djulbegovic B; Kumar A
J Hematol Oncol; 2013 Jan; 6():2. PubMed ID: 23289975
[TBL] [Abstract][Full Text] [Related]
14. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.
Lawless S; Iacobelli S; Knelange NS; Chevallier P; Blaise D; Milpied N; Foà R; Cornelissen JJ; Lioure B; Benjamin R; Poiré X; Minnema MC; Collin M; Lenhoff S; Snowden JA; Santarone S; Wilson KMO; Trigo F; Dreger P; Böhmer LH; Putter H; Garderet L; Kröger N; Yaukoub-Agha I; Schönland S; Morris C
Haematologica; 2023 Apr; 108(4):1105-1114. PubMed ID: 35770529
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
16. Autologous and allogeneic transplantation for multiple myeloma at a single centre.
Couban S; Stewart AK; Loach D; Panzarella T; Meharchand J
Bone Marrow Transplant; 1997 Apr; 19(8):783-9. PubMed ID: 9134169
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Koehne G; Giralt S
Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
[TBL] [Abstract][Full Text] [Related]
18. A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China.
Gu ZY; Dong YJ; Fu XR; Li NN; Liu Y; Wu XX; Wang YN; Li YH; Ren HY; Zhang MZ; Li XF; Wang MH; Wu YM; Liu DH; Wang Z; Hu LD; Huang WR
Chin Med J (Engl); 2021 Jun; 134(13):1584-1592. PubMed ID: 34133361
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.
Pemmaraju N; Tanaka MF; Ravandi F; Lin H; Baladandayuthapani V; Rondon G; Giralt SA; Chen J; Pierce S; Cortes J; Kantarjian H; Champlin RE; De Lima M; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):485-92. PubMed ID: 23769669
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]